Filtered By:
Condition: Ischemic Stroke
Procedure: Lung Transplant

This page shows you your search results in order of date.

Order by Relevance | Date

Total 75 results found since Jan 2013.

Platelet Function and Sildenafil Use During Left Ventricular Assist Device Support
Clinical outcome studies have shown that sildenafil is associated with reduced mortality and thrombotic events such as ischemic stroke during contemporary left ventricular assist device (LVAD) support. Sildenafil has anti-platelet properties but its relation to platelet function during LVAD support is uncertain.
Source: The Journal of Heart and Lung Transplantation - April 1, 2023 Category: Transplant Surgery Authors: O. Saeed, M. Farooq, T. Chinnadurai, J. Ramos, S. Patel, P. Chavez, Y. Rochlani, S. Murthy, J. Shin, S. Vukelic, D. Sims, D. Goldstein, U. Jorde Tags: (136) Source Type: research

Successful Bridge From Va-Ecmo to Heart Transplant in an Adult after Mechanical Thrombectomy for Acute Ischemic Stroke
We present a unique case of a patient who underwent MT for acute ischemic stroke while on VA-ECMO with the resolution of neurological deficits and eventually underwent heart transplantation (HT).
Source: The Journal of Heart and Lung Transplantation - April 1, 2023 Category: Transplant Surgery Authors: S. Riaz, M. Hakim, T.V. Mehta, A. Jaiswal, A. Scatola Tags: (777) Source Type: research

New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

The results of thrombectomy from the arteries of the lower extremities in patients infected with SARS-CoV-2 Omicron variant with different severity of respiratory failure
CONCLUSION: In patients infected with COVID-19 and on artificial lung ventilation, a more aggressive course of the disease is noted, expressed in an increase in laboratory parameters (C-reactive protein, ferritin, interleukin-6, and D-dimer) of the degree of pneumonia (CT-4 in overwhelming number) and localization of thrombosis of the arteries of the lower extremities, mainly in the tibial arteries.PMID:36867526 | DOI:10.1177/17085381231160933
Source: Vascular - March 3, 2023 Category: Surgery Authors: Anton N Kazantsev Alina S Zharova Dmitriy V Shmatov Aslan B Zakeryaev Roman Yu Lider Elizaveta G Kazantseva Goderzi S Bagdavadze Alexander V Korotkikh Victor A Lutsenko Roman V Sultanov Oleg V Lebedev Alexey A Sirotkin Elena V Snopova Petr D Palagin Source Type: research

Independent risk factors for an increased incidence of thromboembolism after lung transplantation
ConclusionsThe incidence of TE after LTX is high, especially in lung transplant recipients with a BMI  >  25 and an age >  55 years as well as cardiovascular risk factors closely associated with the metabolic syndrome. As these patients comprise a growing recipient fraction, intensified research should focus on the risks and benefits of regular screening or a prolonged TE prophylaxis in these patients.Trial registration number DKRS: 00021501.
Source: Journal of Thrombosis and Thrombolysis - December 10, 2022 Category: Hematology Source Type: research

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Central VA-ECMO Support without Full Anticoagulation is Feasible During Lung Transplant
In this study, we analyzed the feasibility of central VA-ECMO without full anticoagulation during lung transplantation. We also analyzed the incidence of morbidity including ischemic and thrombotic complications, stroke, and postoperative outcomes.
Source: The Journal of Heart and Lung Transplantation - April 1, 2022 Category: Transplant Surgery Authors: Y. Yagi, A. Manerikar, A. Bharat, C. Kurihara Tags: (911) Source Type: research

Carotid Endarterectomy Prior to Ventricular Assist Device Placement in a Patient with Cardiogenic Shock
Atherosclerotic disease in the cervical vessels may be a contraindication for implantation of left ventricular assist devices (LVADs). The occurrence of ischemic stroke represents an obstacle to rehabilitation, and its incidence seems to be higher in this population. Carotid endarterectomy (CEA) is a preferable surgical treatment in patients with high bleeding risk. This case report suggests that CEA followed by implantation of LVADs can be feasible.
Source: The Journal of Heart and Lung Transplantation - April 1, 2022 Category: Transplant Surgery Authors: M.S. Lira, R.C. Dantas, D.d. Belfort, S.R. Furquim, C.A. Arag ão, B.R. Gomes, B.S. Biselli, S.M. Ferreira, E.A. Bocchi Tags: (558) Source Type: research

Controlled temperatures in cold preservation provides safe heart transplantation results
ConclusionUsing the SherpaPak system during heart transplantation is safe and not associated with significant recipient morbidity. None of the recipients experienced significant PGD and mortality.
Source: Journal of Cardiac Surgery - January 21, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Macit Bitargil, Osama Haddad, Si M. Pham, Rohan M. Goswami, Parag C. Patel, Samuel Jacob, Magdy M. El ‐Sayed Ahmed, Juan Carlos Leoni Moreno, Daniel S. Yip, Kevin Landolfo, Basar Sareyyupoglu Tags: ORIGINAL ARTICLE Source Type: research

Chronic Rejection and Atherosclerosis in Post-Transplant Cardiovascular Mortality: Two Sides of the Same Coin
Cardiovascular disease (CVD) as defined by the American Heart Association includes ischaemic heart disease, stroke, heart failure and thromboembolism [1]. Solid organ transplantation is associated with an increased risk of CVD morbidity and mortality [2], a relationship which was first observed in the context of kidney transplantation by Foley in 1998 [3]. This manifests clinically as an increased rate of major adverse cardiovascular events (MACE), defined as the composite of cardiac death, non-fatal myocardial infarction, non-fatal stroke, unstable angina and heart failure [4,5].
Source: Heart, Lung and Circulation - November 27, 2021 Category: Cardiology Authors: Afolarin A. Otunla, Kumaran Shanmugarajah, Maria Lucia Madariaga, Alun H. Davies, Joseph Shalhoub Tags: Editorial Source Type: research

New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news